Arcutis Biotherapeutics (NASDAQ: ARQT) net income
Arcutis Biotherapeutics reported a net loss of $16.1m for fiscal 2025; in fiscal 2024 it reported a net loss of $140.0m. Earnings per share were −$0.13.
Fiscal 2025 is the highest of the 7 fiscal years on record for Arcutis Biotherapeutics. It reported a loss in 7 of those 7 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$16.1m | — | −4.3% | −$0.13 |
| 2024 | −$140.0m | — | −71.3% | −$1.16 |
| 2023 | −$262.1m | — | −439.8% | −$3.78 |
| 2022 | −$311.5m | — | −8,449.8% | −$5.66 |
| 2021 | −$206.4m | — | — | −$4.18 |
| 2020 | −$135.7m | — | — | −$3.80 |
| 2019 | −$42.0m | — | — | −$22.78 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Arcutis Biotherapeutics net income compared with its sector
By net income for its latest fiscal year, Arcutis Biotherapeutics ranks 200th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Arcutis Biotherapeutics, −4.3%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 198th | Cerus | −$15.6m | −6.7% |
| 199th | Axogen | −$15.7m | −7.0% |
| 200th | Arcutis Biotherapeutics | −$16.1m | −4.3% |
| 201st | Palisade Bio | −$16.8m | — |
| 202nd | Alpha Teknova | −$17.3m | −42.6% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Arcutis Biotherapeutics
- How much did Arcutis Biotherapeutics earn in fiscal 2025?
- Arcutis Biotherapeutics reported a net loss of $16.1m for fiscal 2025. In fiscal 2024 it reported a net loss of $140.0m.
- What are the earnings per share of Arcutis Biotherapeutics?
- They were −$0.13 in fiscal 2025, compared with −$1.16 in fiscal 2024.
- Where does Arcutis Biotherapeutics rank in its sector by net income?
- It ranks 200th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Arcutis Biotherapeutics come from?
- From the annual report (Form 10-K) that Arcutis Biotherapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Arcutis Biotherapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Arcutis Biotherapeutics: the Arcutis Biotherapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.